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Abstract
Background and aim: Recent studies focusing on the discovery of common alterations across cases suffering 
from follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) have reported loss of heterozygosity (LOH) 
and deletions events targeting the 15q21 region, indicating the relevance of this region in the lymphomagenesis of 
FL and DLBCL. Herein, we investigated the genetic structure of this region by studying identified LOH and copy-loss 
events and examined this region in the lymphomagenesis of FL and DLBCL. 
Methods: Fine mapping of the genomic region between the 15q15.1 and 15q21.1 loci was performed using 
data from copy number variation (CNV) and high resolution LOH analyses of FL (n=21) and DLBCL (n=21) cases. 
Validation of LOH of this region was performed using microsatellites followed by quantitative-PCR (qPCR) to 
measure the transcriptional abundance of TP53BP1 and B2M. Also, direct sequencing of exons 1 and 2 of B2M was 
performed on tumor DNA from 24 FL and 23 DLBCL samples. 
Results: The integration of LOH and CNV data identified copy-loss alterations at the 15q21 loci spanning a 7.5 
Mb region, covering two LOH regions, termed LOH-1 and LOH-2. The LOH-1 region spans 3.4 Mb and contains 53 
genes, from which TP53BP1 (tumor-protein-p53-binding-protein-1) and B2M (Beta-2-Microglobulin) were identified 
as the most likely target genes due to their roles in DNA double strand break (DSB) repair and immune recognition, 
respectively. Expression analyses revealed a significant up-regulation of TP53BP1 in NHL with LOH, but no 
significant changes in B2M expression were observed. Direct sequencing of exons 1 and 2 in B2M in FL and DLBCL 
identified two monoallelic microdeletions associated with DLBCL.
Conclusion: This study identified that deletion mapping to the 15q21 locus cover two LOH regions. LOH of the 
TP53BP1 and B2M genes appear to be common alterations in FL and DLBCL tumorigenesis.
Keywords: LOH; Copy-loss events; TP53BP1; B2M; DLBCL and FL 
lymphomagenesis
Introduction
Follicular lymphoma (FL) and diffuse large B-cell lymphoma 
(DLBCL) are responsible for over 60% of newly diagnosed cases of 
Non-Hodgkin’s lymphoma (NHL) [1,2]. FL and DLBCL, have indolent 
and aggressive clinical courses, respectively; however, they share the 
same origin (Germinal B-cell centre), but exhibit high heterogeneity 
in their morphology, clinical outcome and genetic makeup. 
Approximately 20% of FL cases transform to DLBCL, characterised 
by the acquisition of a wide array of secondary alterations, including 
structural genomic alterations (i.e. translocations including c-MYC, 
BCL6 genes) and genetic mutations (e.g. TP53), following constitutive 
BCL-2 overexpression, as a result of the translocation, t(14;18)
(q32;q21) [3-6]. Nonetheless, despite differences in genetic aberrations 
underlying the diverse tumor biology of FL and DLBCL, the presence 
of common genomic alterations between FL and DLBCL indicates that 
lymphomagenesis of FL and DLBCL may be caused by inactivation 
or activation of shared genes and pathways, which can be crucial for 
survival and development of these B-cell lymphomas [7]. 
The identification of novel tumor suppressor genes (TSGs) and 
their role in oncogenesis is paramount for a better understanding 
of the etiology and pathogenesis of cancer. TSGs negatively regulate 
vital pathways for the proliferation and sustenance of the malignant 
phenotype of cancer cells; as such, they are often targets of genomic 
and genetic alterations that disrupt their function to trigger oncogenic 
processes. Loss of heterozygosity (LOH) analysis is a useful tool for the 
identification and study of inactivated TSGs by copy-loss (hemizygous 
deletions) or copy-neutral events (chromosomal duplications, genomic 
or epigenetic mutations) [8,9]. The recent use of SNP array data from 
an unpaired cohort of tumors has enabled the inference of LOH events 
in tumor samples without the need for comparison to their normal 
counterparts [8,10].
Using high resolution LOH analysis, we recently reported LOH 
in common regions across FLs and DLBCLs including candidate 
tumor suppressor genes (TSGs) within these regions [11]. The precise 
identification of genes within these commonly affected regions 
is relevant for a better understanding of the common pathogenic 
mechanisms that may play a role in the lymphomagenesis of FL and 
DLBCL. One of the most common LOH regions, in FL and DLBCL 
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cases, spanned the chromosomal bands 15q15.1 and 15q21 [11]. 
LOH of this genomic region has also been described in pediatric 
glioblastomas [12]. Several alterations within and surrounding this 
region has also been described in B-cell lymphomas. In a previous 
study, integrating copy number and gene expression data analyses, we 
identified that loss of 15q21 was a shared alteration between FLs and 
DLBCLs [7]. Additionally, deletion of both 15q and 8p was correlated 
with poor prognosis in DLBCL cases, and loss of 15q23 has been 
considered as a secondary hit in the transformation of FL to DLBCL 
[3,13]. Furthermore, a previous paired high resolution LOH study 
identified a 70 Mb region (15q13.3-15q26.3) as a target of LOH-driving 
copy-neutral events in FL [14]. 
Hence, based on the discovery that the deletion of 15q21 and LOH 
of the region 15q15.1-15q21 are common alterations across FLs and 
DLBCLs and the potential for TSGs located within this region to play a 
crucial role in the lymphomagenesis of these B-cell lymphomas [7,11], 
we undertook copy number and LOH analyses, integrating this data 
for fine-mapping of this region. This approach was used to determine 
overlapping regions affected by LOH and copy-loss events in these 
NHL subtypes, and to identify candidate TSGs targeted by these events. 
By undertaking this integrative approach, we identified that the region 
targeted by copy-loss events spans 7.5 Mb and contains two specific 
LOH regions, named as LOH-1 and LOH-2, which span a region of 
3.4 Mb and 1.1 Mb, respectively. We then focused our studies on the 
LOH-1 region and identified the TP53BP1 (tumor protein p53 binding 
protein 1) and B2M (Beta-2-Microglobulin) genes as commonly 
inactivated TSGs in FLs and DLBCLs. Interestingly, TP53BP1 and B2M 
have previously been implicated in the lymphomagenesis of DLBCL 
[15-19]. However, this study supports very recent evidence implicating 
the inactivation of B2M in FL transformation and DLBCL pathogenesis 
[15,20,21], and it is the first study to suggest a role for TP53BP1 in the 
lymphomagenesis of both FL and DLBCL. In addition, two monoallelic 
microdeletions were identified by sequence screening on exons 1 and 
2 of B2M in FL and DLBCL, suggesting that somatic mutations are not 
the common LOH drivers of LOH events targeting this TSG. 
Materials and Methods
Patients and controls
Genomic DNA and total RNA were isolated from fresh-frozen 
tumor biopsies of NHL patients and from normal tissue samples of 
controls, following previously described methodologies [7,10,11]. All 
tumor tissue samples were collected at diagnosis, excluding relapsed/
refractory cases. Cases with transformed FL or FL grade IIIB as well 
as cases with immunosuppression-associated lymphomas were not 
included in this study. 
Fine mapping of the genomic region 15q15.1-15q21.1 
Previously published data from copy number variation and high 
resolution LOH analyses of DLBCL (n=21) and FL (n=21) cases was 
used to perform fine mapping of the chromosomal region between the 
15q15.1 and 15q21.1 loci to identify genes within this segment targeted 
by copy-loss (deletions) and LOH events across FLs and DLBCLs 
[7,11]. An integrative analysis of these two genomic approaches was 
carried out by enrichment of an LOH-Manhattan plot on chromosome 
15 with the False Discovery Rates (FDR) Q-values from Genomic 
Identification of Significant Targets in Cancer (GISTIC) scores [7,11]. 
Fine-mapping of this region was carried out using the Integrative 
Genomics Viewer (IGV, v1.5) program. 
A statistical overlap approach using a hypergeometric distribution 
of all genes located within the LOH-1 and LOH-2 regions was 
performed to investigate and overlap these LOH genes with collections 
of curated gene sets, including canonical pathways, Biocarta, KEGG, 
and Reactome, from the Molecular Signature Database (MsigDB, v3.1). 
The significance level for this analytical approach was set at α<0.05 with 
a FDR <0.05
TP53BP1 and B2M expression analyses 
TP53BP1 and B2M mean fluorescence intensity values from an 
Illumina Sentrix Human-6 (v2.0) array of 14 FLs and 17 DLBCLs with 
available LOH data were analyzed as previously described [11]. In 
order to investigate the effect LOH on TP53BP1 and B2M expression, 
TP53BP1 or B2M expression was compared between cases with RET 
(retention) and LOH. Cell of origin (COO) subclassification of DLBCL 
samples was based on criteria established by Shipp [22], resulting in 10 
out 21 DLBCL cases classified as GCB-like subtype and 11 out of 21 as 
non-GCB-like subtype.
Transcript abundance of TP53BP1 and B2M was measured by 
quantitative PCR (qPCR). Briefly, cDNA was reverse transcribed 
from total RNA isolated from tonsil samples of 6 healthy individuals 
and from 41 tumor tissues with high resolution LOH data as previ-
ously described [11]. Expression levels of TP53BP1 and B2M were de-
termined by normalization with to RPL13A using the relative quan-
tification (2-∆∆Ct) method. The oligonucleotide sequences used were: 
TP53BP1-F (5’-TTGCCATGCCAACCAGCTCCAG-3’), TP53BP1-R 
(5’-TTCACGGGGTTGCCAGTCCAG-3’), B2M-F (5’-TGCCTGCC-
GTGTGAACCATGT-3’),B2M-R (5’-TGCGGCATCTTCAAACCTC-
CATGA-3’), RPL13A-F (5’-ATCTTGTGAGTGGGGCATCT-3’) and 
RPL13A-R (5’-CCCTGTGTACAACAGCAAGC-3’). All qPCR reac-
tions were performed as previously described [11]. Expression levels of 
TP53BP1 and B2M were compared between NHL cases with LOH and 
RET calls using an independent t-test (α<0.05).
Sequence analysis 
Exons 1 and 2 of B2M were sequenced in gDNA from the tumor 
samples of 24 FL and 23 DLBCL cases. Oligonucleotide sequences 
used were: Exon 1_F (5’-GGCGCCGATGTACAGACAGCA-3’), 
exon 1_R (5’-GGCGGGCCACCAAGGAGAAC-3’), exon 2_F 
(5’-GGAGGTGGCTTGTTGGGAAGGT-3’) and exon 2_R 
(5’-AGATGGGATGGGACTCATTCAGGGT-3’). Bidirectional direct 
sequencing of 40 ng of the cleaned PCR amplicon was carried out using 
the BigDye Terminator cycle sequencing kit v3.1 in a GeneScan® 3130 
(Applied Biosystems, Austin, TX, USA), following the manufacturer’s 
guidelines. Mutational analysis of B2M sequences was performed using 
Geneious Basic software (version 5.5.6, Biomatters). 
Results
Fine mapping of the 15q15.1 - 15q21 genomic region reveals 
that LOH of TP53BP1 and B2M genes are common alterations 
in DLBCLs and FLs 
LOH data for chromosome 15 was extracted from a previously 
performed high resolution LOH analysis on SNP array data of NHL 
cases. LOH of the region comprising the chromosomal bands 15q15.1 
and 15q21.1 was identified from this data, as previously reported, 
and was common across DLBCL and FL cases [11] (Figure 1A). 
Enrichment of this LOH region with the GISTIC false discovery rates 
(FDR) for deletion obtained from Green et al., [7], determined that this 
LOH region is part of a larger genomic region of 7.5 Mb, targeted by 
common copy-loss alterations across both NHL subtypes (Figure 1B). 
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Integration of LOH and CNV data determined that two LOH regions, 
termed LOH-1 and LOH-2, are located within this commonly deleted 
region (Figure 1C), suggesting that LOH events target more specific, 
small regions than copy-loss events and that copy-loss events do not 
necessarily drive LOH.
Fine-mapping determined that the LOH-1 region spans 3.4 Mb 
and comprises of approximately 53 genes; whereas, the LOH-2 region 
covers a 1.1 Mb genomic portion that contains 14 genes (Table S1). 
Statistical overlapping of genes located within both LOH regions found 
a significant enrichment of Arginine and Proline metabolism genes 
(hsa00330; k/K score=0.0556; P=0.0000176; FDR q-value=0.0255) 
in LOH-1 including GATM (glycine amidinotransferase), CKMT1A 
(creatine kinase, mitochondrial 1A) and CKMT1B (creatine kinase, 
mitochondrial 1B). Loss of heterozygosity of the LOH-1 region 
was validated by a significant decrease of heterozygosity rates for 
microsatellites targeting the LOH-1 region in an unmatched cohort of 
controls and NHL cases (Data not shown).
Amongst the 53 genes located within the LOH-1 region (Table 
S1), the tumor suppressor genes TP53BP1 (Tumor Protein p53 
Binding Protein 1) and B2M (Beta-2-Microglobulin) were identified 
as the most likely target genes of LOH-driving events in FLs as well as 
in DLBCLs. This was based on the role that TP53BP1 and B2M play 
in mechanisms such as DNA double strand break (DSB) repair and 
immune recognition, and the previously implicated role of these TSGs 
in the lymphomagenesis of DLBCL [15-19]. In addition, the location 
of the microsatellite D15S917 (located between the TP53BP1 and B2M 
loci) validated previously identified LOH associated with these TSGs 
and implicated this as a common event in the lymphomagenesis of FL 
and DLBCL. As such, we selected these two genes for more detailed 
analyses. LOH of TP53BP1 in 45% (19/42) of total NHL cases, in 43% 
(9/21) of DLBCL cases and in 48% (10/21) of FL cases. LOH of B2M 
was also detected in 43% (18/42) of total NHL cases, in 48% (10/21) of 
DLBCL cases and in 38% (8/21) of FL cases. In addition, 58% (11 out of 
19) and 61% (11 out of 18) of cases exhibited LOH for both TP53BP1 
and B2M, respectively.
Effect of LOH on expression of TP53BP1 and B2M
TP53BP1 was significantly upregulated in NHL cases with LOH 
of TP53BP1: Initial analysis of available TP53BP1 mean fluorescence 
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Figure 1: Fine mapping of the chromosomal region 15q15.1-15q21.1 revealed that this region is a common target in FLs and DLBCLs. A) A larger genomic region 
of 7.5 Mb (hg18.chr15:40190047-47715466) was found to be commonly targeted by copy-loss events across NHL cases, using the False Discovery Rates (FDR) 
Q-values from GISTIC scores for deletions, previously obtained by Green et al. [7]. B) In addition, it was determined that this commonly deleted region contained 2 
LOH regions, LOH-1 region spanning over 3.4 Mb (hg18.chr15:40355785-43764621) and containing 53 genes, and LOH-2 region (hg18.chr15:49759265-50872400) 
covering a region of 1.1 Mb and harboring 14 genes. Additionally, we observed a third LOH region (LOH-3), which is not further described in this manuscript as it is 
located outside of the region targeted by copy-loss events. C) Interestingly, the genes TP53BP1 and B2M were identified to be targeted by LOH events in the LOH-1 
region. Localization of microsatellites (D15S146 and D15S917) used for validation of the LOH within the region 15q15.1-15q21.1 are indicated.
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intensity values, from an Illumina Sentrix Human-6 (v2.0) Expression 
Beadchip, from patients with known LOH status (31 out of 42 NHL 
cases) [7], did not reveal any significant effect of LOH on TP53BP1 
expression between cases with RET and LOH calls in NHLs (847 vs. 
872; P=0.715), FLs (795 vs. 882; P=0.442) and DLBCL (891 vs. 862; 
P=0.718) (Figure S1). However, when we examined TP53BP1 gene 
expression by qPCR in 41 NHL cases with available LOH data, a 
significant up-regulation of TP53BP1 in NHL cases with LOH (1.1 vs. 
1.6; P=0.019) with trends towards up-regulation in FL (1.15 vs. 1.53; 
P=0.094) and DLBCL (1.10 vs. 1.71; P=0.098) cases with LOH (Figure 
2) was demonstrated. In addition, although not significant, there was a 
trend toward up-regulation in GCB-like cases (0.82 vs. 1.90; P=0.157) 
but not in non-GCB-like cases (1.20 vs. 1.0; P=0.687) (Figure S2).
Loss of heterozygosity did not show a significant effect on 
B2M expression in FLs and DLBCLs: By comparing B2M mean 
fluorescence intensity values [7] between NHL cases with RET and 
LOH, no significant difference was observed in NHL (17661 vs. 17136; 
P=0.688), FL (16727 vs. 18142; P=0.293) or DLBCL (18783 vs. 16532; 
P=0.311) cases (Figure S3). In addition, analysis of B2M expression by 
qPCR showed no significant difference between cases with LOH and 
RET calls in NHLs (1.23 vs. 1.47; P=0.398), FLs (1.16 vs. 1.54; P=0.127) 
and DLBCLs (1.33 vs. 1.41; P=0.870) (Figure 3). LOH events had no 
significant effect on B2M expression in GCB-like DLBCL cases (0.76 vs. 
1.50; P=0.109) and non-GCB-like DLBCL cases (1.71 vs. 1.28; P=657) 
(Figure S4). 
Monoallelic microdeletions in B2M found in two DLBCL cases 
with LOH: To determine whether somatic mutations are the driving 
cause of LOH associated with B2M in our case cohort, we performed 
sequence screening in exons 1 and 2 of the B2M gene in 47 NHLs, 
including 24 FLs and 23 DLBCLs. Exons 1 and 2 of the B2M gene 
were selected for this mutational screening as a previous report only 
identified somatic mutations in the exons 1 and 2 but not in the exon 
3 of B2M [15]. Thus, as a result of this sequence screening performed 
in our cohort, no mutations were found in FLs; however, a novel 
mutation ∆12 bp (77-88 bp) with an insT (76-77 bp) was identified in 
one DLBCL case (Figure 4A). In addition, a ∆CT (98-99 bp) deletion 
was identified in another DLBCL patient (Figure 4B). Both ∆12 bp (77-
88 bp) and ∆CT (98-99 bp) are frame-shift mutations, located in exon 
1, and induce premature stop codons producing truncated proteins 
(51aa and 54aa respectively) with an associated loss of the functional 
MHC class I domain (28-83 residues).
Discussion 
The integration of genomic data from copy number and high 
resolution LOH analyses of tumor DNA from FL and DLBCL cases 
[7,11], allowed us to perform fine mapping of the region between the 
chromosomal bands 15q15.1 and 15q21.1. Using this approach, we 
found that the deleted region mapping at 15q21, previously reported 
as a common alteration across FLs and DLBCLs [7], spans 7.5 Mb and 
contains two LOH regions, termed LOH-1 and LOH-2. These findings 
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suggest that LOH drivers could be more target-specific than copy-loss 
events [14], possibly by inactivating regions harboring TSGs. Moreover, 
it also suggests that copy-loss events do not exclusively drive LOH, as 
these two LOH regions are separated by a region with the same deletion 
rate. Recently, the detection of this 7.5 Mb deleted region was further 
validated by the identification of a deletion-targeted region of 6.2 Mb at 
the 15q21.1 locus in a large cohort of DLBCL cases [23], which mostly 
overlaps with the 7.5 Mb region reported in this study. However, this 
6.2 Mb region encompasses the LOH-1 region but excludes the LOH-2 
region [23]. The LOH-1 and LOH-2 regions detected in the present 
study span 3.4 Mb and 1.1 Mb, respectively. Furthermore, a significant 
reduction of heterozygosity rates for a microsatellite in NHL cases 
validated the LOH observed in LOH-1. The LOH-1 region contains 
approximately 53 genes with significant enrichment observed for the 
Arginine and Proline metabolism pathway. This indicates that this 
LOH region may play an important role in the lymphomagenesis of 
FL and DLBCL, as inactivation of genes within this region can disrupt 
or reprogram metabolic pathways including the glutamine-proline-
arginine circuit, potentially enabling highly efficient malignant B-cell 
metabolic activity [24, 25].
Amongst the genes located within LOH-1, we identified the tumor 
suppressor genes TP53BP1 and B2M, located at 15q15.3 and 15q21 
respectively. These TSGs have been previously implicated in DLBCL 
lymphomagenesis [15-18,23]. However, this is the first study to 
implicate TP53BP1 and B2M in FL lymphomagenesis where we have 
identified LOH-driving events targeting these TSGs in DLBCLs and 
FLs. Furthermore, we observed that although TP53BP1 and B2M are 
located within a common LOH region (LOH-1 region) and their LOH 
calls are significantly correlated, there is a discrepancy of over 30% 
of LOH calls for these two TSGs, suggesting the driving mechanism 
of LOH may differ between TP53BP1 and B2M. In fact, the higher 
frequencies of LOH of TP53BP1 and B2M compared to the previously 
reported frequencies for the deletion of the 15q21.1 locus in FL and 
DLBCL cases [7] indicate that LOH of these TSGs are not only driven 
by copy-loss events. Hence, the genetic mechanisms underlying LOH 
of TP53BP1 and B2M in the tumorigenesis of FL and DLBCL as well 
as the effect of LOH-driving events on the inactivation of these TSGs 
require further investigation. 
The present study implicates LOH of TP53BP1 and its potential 
inactivation, as a common event in the lymphomagenesis of both FL 
and DLBCL. Several lines of evidence indicate that TP53BP1 can play 
an important role in B-cell lymphomagenesis. For example, single-
copy deletions targeting the TP53BP1 locus in DLBCL cases involve 
TP53BP1 haploinsufficiency in DLBCL pathogenesis [18]. TP53BP1 
participates in the rejoining of double strand breaks (DSBs) induced 
during normal B-cell development, such as class switch recombination 
(CSR), V(D)J recombination and non-homologous end-joining 
(NHEJ) [26-34]. Hence, TP53BP1 inactivation may contribute to the 
high frequency of translocations involving immunoglobulin heavy 
chain loci with oncogenes (i.e. BCL2, BCL6 and MYC) observed in B-cell 
lymphomas [35-38]. In murine models, haploinsufficiency of TP53BP1 
induced genomic instability and impaired DNA double strand break 
(DSB) repair, has been demonstrated to correlate with a high incidence 
of thymic and B-cell lymphomas [29,31]. The implication of LOH of 
TP53BP1 in FL lymphomagenesis suggests a crucial role for TP53BP1 
LOH as the secondary hit in the transformation of FL to DLBCL, 
driving the acquisition of secondary genomic and genetic alterations 
through disruption of DSB repair mechanisms in CSR during B-cell 
development [3,4,32,36]. However, it is likely that LOH of TP53BP1 
has a synergistic effect with TP53 silencing during FL transformation, 
resulting in the reduced response to DSB of FL cells undergoing 
malignant transformation [5,39]. This is supported by the observed 
significant increase in tumor development, genomic instability and 
lymphomagenesis in mice lacking TP53 expression resulting in null 
or reduced TP53BP1 expression [29,33]. In addition, recent evidence 
showing that copy-number alterations (CNAs) perturb the TP53 
pathway in DLBCLs [23], suggest that LOH of TP53BP1 may also play a 
role in disruption of the TP53 pathway, influencing FL transformation 
as well as DLBCL pathogenesis. Moreover, TP53 and TP53BP1 might 
also be implicated in DLBCL chemoresponsiveness as cases with 
deletions of 8p, 15q (TP53BP1) and 17p (TP53) exhibit poor responses 
to R-CHOP-21 therapy [13]. 
A significant up-regulation of TP53BP1 was observed in NHL cases 
with LOH. This is in contrast to the significant down-regulation of 
TP53BP1 in DLBCL cases with hemizygous deletions of the TP53BP1 
locus [18], supporting the hypothesis that LOH of TP53BP1 may be the 
result of copy-neutral events in FL and in DLBCL. However, although we 
observed TP53BP1 up-regulation in our LOH case cohort, the concept 
“LOH” corresponds to the functional inactivation of a TSG by genetic 
A. B.
D
LB
C
L1
4
D
LB
C
L1
0
N
O
R
M
A
L
N
O
R
M
A
L
Single bp insertion
12bp deleted region 2bp deleted region
Frame-shift Frame-shift
Figure 4: Mutational screening of exons 1 and 2 of B2M across 24 FLs and 23 DLBCLs identified A) a novel monoallelic ∆12bp (77-88 bp) with an insT (76-77 bp) in 
a DLBCL patient and B) a ∆CT (98-99 bp) in another DLBCL case.
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mechanisms (copy-neutral or copy-loss events) in a broader cellular 
perspective, rather than a down-regulatory effect (happloinsufficiency) 
[9,40]. Thus, up-regulation of TP53BP1 may be due to the cellular 
response against LOH-driving events causing inactivation of TP53BP1, 
or aberrant transcriptional mechanisms induced by copy-neutral 
events (duplication, somatic mutations). Therefore, additional “driver” 
alterations of TP53BP1 LOH events as well as the effect of these on the 
TP53BP1 function, need to be further examined as somatic mutations 
targeting the TP53BP1 locus not identified in NHL cases by previous 
whole exome sequencing studies [16,17]. 
Another TSG identified and studied within this LOH region was 
the beta-2-microglobulin (B2M) gene. LOH of B2M herein identified as 
a common event in FL and DLBCL has been reported in colorectal and 
bladder carcinomas, as well as in testicular and central nervous system 
(CNS) DLBCL [41,42]. Recent studies have reported that B2M is widely 
targeted and inactivated by somatic mutations and deletions in DLBCL 
cases [15-17,41,42]. Additionally, recent lines of evidence have identified 
mutations targeting the B2M locus in a small fraction of transformed 
FL cases [20,21]. In the present study, mutational screening of exons 
1 and 2 of B2M in FL and DLBCL cases, detected two monoallelic 
microdeletions in two DLBCL cases with LOH, one novel ∆12 bp (77-
88 bp) with an insT (76-77 bp) and another previously reported ∆CT 
(98-99 bp). Both deletions are frameshift mutations and predicted to 
produce two truncated proteins (51 aa and 54 aa respectively) with a 
loss of the MHC class I domain in both cases. Therefore, it is likely 
that these mutations inactivate the function of B2M as instability of the 
truncated B2M proteins would likely have a dominant negative effect 
on the assembly of the major histocompatibility complex class I (MHC 
I) complex [15,43]. In contrast, based on the detection of only two 
mutations in two DLBCL patients with LOH and the lower frequency 
of deletions in comparison to the frequency of LOH in our cohort of 
FLs and DLBCLs, we suggest that additional genetic mechanisms could 
induce LOH of this TSG, and subsequently drive its inactivation in 
FLs and DLBCLs. This observation is supported by the low frequency 
of mutations targeting B2M in FL cases undergoing transformation 
[20,21]. In addition, it is important to mention that despite only 
detecting somatic mutations in 2 out of 23 DLBCL cases, the frequency 
of these mutations in our population (8.7%) is not significantly lower to 
the observed frequencies of somatic mutations targeting the B2M loci 
in previous studies analyzing a larger cohort of DLBCL cases, which 
vary between 9% and 13% [15,17]. Thus, the low frequency of somatic 
mutations across these studies, including the present study, support 
our hypothesis suggesting that LOH events in addition to mutations 
may also be driving inactivation of this TSG. 
The inactivation of B2M, a small protein required for the assembly 
of the HLA class I molecule, is one of the mechanisms that disables 
the recognition of the HLA class I complex by CD8+ cytotoxic T-cell 
lymphocytes (CTL), enabling tumor cells to escape immune surveillance 
and growth control [15-17,41, 43,44]. Although inactivation of B2M 
has been previously detected in DLBCLs [15-17,41], the demonstration 
of LOH of the B2M locus as a common event across FL and DLBCLs 
suggests that evasion of CTL-mediated regulatory mechanisms may 
play a role in FL and DLBCL lymphomagenesis. Additionally, using 
pathway analyses, we have recently reported the direct interaction of 
B2M with GRB2 (growth factor receptor-bound protein 2), an adaptor 
protein that activates the RAS-MAPK pathway, and a direct interaction 
of GRB2 with PTPRJ (protein tyrosine phosphatase receptor type J), a 
negative regulator of B-cell survival pathways, such as MAPK, PI3K, 
VEGF [45-49]. Thus, the presence of LOH events targeting the TSGs 
B2M and PTPRJ suggests that B2M inactivation is not an isolated event 
in lymphomagenesis but part of an orchestrated network of oncogenic 
hits that inactivate key TSGs responsible for the regulation of critical 
oncogenic pathways and thus, induce the malignant phenotype of these 
lymphomas [45]. In addition, in this study, the transcript abundance of 
B2M did not differ significantly between cases with retention and LOH. 
This pattern was also observed, in a previous study, between DLBCL 
cases with and without inactivation of B2M, where even the presence 
of detectable mRNA levels of B2M in cases harboring B2M missense 
variants expressed significantly low protein levels of B2M [15]. Thus, 
the no correlation between transcript and protein levels of B2M suggest 
that despite transcript levels detectable in patients with inactivated 
copies of B2M, the protein instability resulting from the presence of 
missense mutations can induce undetectable levels of protein in these 
cases, as previously suggested [15]. Hence, based on this finding, it is 
likely that DLBCL cases with LOH of B2M exhibit low protein levels 
regardless their B2M transcript abundance; however, further functional 
studies will provide a much clearer insight of the effect of LOH in B2M 
protein levels, in the context of NHL pathogenesis. 
In conclusion, the LOH and potential inactivation of the TSGs 
located within the 15q15.1-15q21 genomic region may be an important 
target in the tumorigenesis of FL and DLBCL due to their involvement 
in key pathways of tumor survival. In addition, this study implicates 
LOH of TP53BP1 and B2M, identified as a shared alteration across 
FL and DLBCL, in the lymphomagenesis and progression of these 
B-cell lymphomas. However, further genetic and functional studies are 
required to determine the driving causes of LOH of TP53BP1 and B2M. 
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